It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Pseudotime analysis with single-cell RNA-sequencing (scRNA-seq) data has been widely used to study dynamic gene regulatory programs along continuous biological processes. While many methods have been developed to infer the pseudotemporal trajectories of cells within a biological sample, it remains a challenge to compare pseudotemporal patterns with multiple samples (or replicates) across different experimental conditions. Here, we introduce Lamian, a comprehensive and statistically-rigorous computational framework for differential multi-sample pseudotime analysis. Lamian can be used to identify changes in a biological process associated with sample covariates, such as different biological conditions while adjusting for batch effects, and to detect changes in gene expression, cell density, and topology of a pseudotemporal trajectory. Unlike existing methods that ignore sample variability, Lamian draws statistical inference after accounting for cross-sample variability and hence substantially reduces sample-specific false discoveries that are not generalizable to new samples. Using both real scRNA-seq and simulation data, including an analysis of differential immune response programs between COVID-19 patients with different disease severity levels, we demonstrate the advantages of Lamian in decoding cellular gene expression programs in continuous biological processes.
Pseudotime analysis is prevalent in single-cell RNA-seq, but it remains challenging to perform it across multiple samples and experimental conditions. Here, the authors develop Lamian, a computational framework for multi-sample pseudotime analysis that adjusts for biological and technical variation to detect gene program changes along cell trajectories and across conditions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 The Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Columbia University, Department of Biostatistics, Mailman School of Public Health, New York, USA (GRID:grid.21729.3f) (ISNI:0000 0004 1936 8729)
2 The Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Duke University School of Medicine, Department of Biostatistics and Bioinformatics, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
3 University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Institute for Immunology, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, USA (GRID:grid.489192.f) (ISNI:0000 0004 7782 4884); Dana-Farber Cancer Institute, Department of Cancer Biology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910)
4 University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); University of Pennsylvania, Institute for Immunology, Perelman School of Medicine, Philadelphia, USA (GRID:grid.25879.31) (ISNI:0000 0004 1936 8972); Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, USA (GRID:grid.489192.f) (ISNI:0000 0004 7782 4884)
5 The Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)